<DOC>
	<DOCNO>NCT01531894</DOCNO>
	<brief_summary>GSK2110183 orally administer , pan-AKT kinase inhibitor demonstrate nonclinical activity hematologic well solid tumor cell line xenograft model . In First Time In Human ( FTIH ) trial , monotherapy GSK2110183 dose orally , daily show encouraging activity subject hematologic malignancy . This multicenter , non-randomized , open-label , treatment continuation 'rollover ' study design provide continued access eligible subject previously participate GSK2110183 study ( parent study ) sponsor GlaxoSmithKline ( GSK ) another research organization work behalf GSK . Eligible subject must receive clinical benefit continue treatment acceptable safety profile GSK2110183 . Subjects participate GSK2110183 combination study approve anti-cancer agent also eligible enroll rollover study . Subjects participate combination study two investigational compound ( one GSK2110183 ) eligible rollover study . Subjects enrol cohort base duration treatment receive parent study . Safety assessment ( physical examination , vital sign measurement , 12-lead electrocardiogram , echocardiograms multiple-gated acquisition scan , clinical laboratory assessment monitor adverse event ) evaluate study . Disease assessment perform use local standard care image practice criterion appropriate disease type location .</brief_summary>
	<brief_title>Continuation Study Oral AKT Inhibitor GSK2110183</brief_title>
	<detailed_description />
	<criteria>Has provide sign informed consent study . Is currently participate GSK2110183 study ( monotherapy combination approve anticancer agent ) sponsor GSK another research organization work behalf GSK . Currently benefit continue treatment acceptable safety profile GSK2110183 determine investigator follow previous treatment GSK2110183 either monotherapy part combination treatment regimen . Continued ability swallow retain orally administer study treatment ( ) clinically significant GI abnormality may alter absorption malabsorption syndrome major resection stomach bowel . Male subject female partner childbearing potential must willing continue practice acceptable method contraception use parent study rollover study least 16 week last dose GSK2110183 . Female subject childbearing potential , defined parent study , must willing continue practice acceptable method contraception use parent study rollover study least 4 week last dose GSK2110183 . Female subject childbearing potential , defined parent study , must negative serum pregnancy test time transition study . Maintain performance status score 0 2 accord Eastern Cooperative Oncology Group ( ECOG ) scale Subjects Type II diabetes allow HbA1C le 8 percent study entry . Have adequate organ system function Permanent discontinuation GSK2110183 parent study due toxicity disease progression . Concomitant use type anticancer treatment study parent protocol . Local access commercially available GSK2110183 . Current use prohibitive medication ( ) Current use anticoagulant Any unresolved toxicity great Grade 2 , except alopecia , ( National Cancer InstituteCommon Toxicity Criteria Adverse Events [ NCICTCAE ] , version 4.0 ) parent study treatment time transition study . History HIV infection . Peripheral neuropathy great Grade 1 History hepatitis B C infection ( subject evidence clear hepatitis B permit ) . Evidence severe uncontrolled systemic disease ( e.g. , unstable , uncompensated respiratory , hepatic , renal , metabolic cardiac disease ) . QTcF interval great 500 msecs time transition study . Other clinically significant ECG abnormality include 2nd degree ( Type II ) 3rd degree atrioventricular ( AV ) block . Evidence current Class II , III , IV heart failure define New York Heart Association [ NYHA , 1994 ] functional classification system time transition study . Symptomatic untreated leptomeningeal , CNS brain metastasis spinal cord compression time transition study . Lactating female female becomes pregnant prior transition study . Previously diagnose diabetes mellitus Type I . Subjects Type II diabetes allow entry criterion fulfil Any serious and/or unstable preexist medical , psychiatric disorder condition time transition study could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator GSK Medical Monitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>GSK2110183</keyword>
	<keyword>hematologic malignancy</keyword>
	<keyword>AKT inhibitor</keyword>
	<keyword>cancer</keyword>
	<keyword>safety</keyword>
</DOC>